PR Newswire PharmaOriginal article
Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, and stroke) in adults with type 2 diabetes compared to switching to Mounjaro® (tirzepatide), in real-world analysis at EASD
Data ReadoutpositiveOzempicMounjaroPositive
AI Analysis
Summary
A real-world analysis presented at EASD showed that semaglutide 2 mg was associated with a statistically significant 6% lower risk of major adverse cardiovascular events compared to switching to tirzepatide in adults with type 2 diabetes.
Outcome Details
Semaglutide 2 mg associated with 6% lower risk of major adverse cardiovascular events compared to switching to tirzepatide in real-world analysis
Importance:6/10
Sentiment:
0.70
cardiovascularreal-world evidencetype 2 diabetescomparative efficacyMACEEASD
Related Companies
Read the original article
Published by PR Newswire Pharma on September 29, 2026 10:00 AM